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Abstract
Background: Although considerable research has focused on the etiology and symptomology of adductor focal
laryngeal dystonia (AD-FLD), little is known about the correlation between clinicians’ ratings and patients’
perception of this voice disturbance. This study has five objectives: first, to determine if there is a relationship
between subjects’ symptom-severity and its impact on their quality of life; to compare clinicians’ ratings with
subjects’ perception of the individual characteristics and severity of AD-FLD; to document the subjects’ perception
of changes in dysphonia since diagnosis; to record the frequency of voice arrest during connected speech; and,
finally, to calculate inter-clinician reliability based on results from the Unified Spasmodic Dysphonia Rating Scale
(USDRS) (Stewart et al, J Voice 1195-10, 1997).
Methods: Sixty subjects with AD-FLD who were receiving ongoing injections of BoNT participated in this study.
Subjects’ mean age was 60.78 years and their mean duration of symptoms was 16.1 years. Subjects completed the
Disease Symptom Questionnaire (DSQ) (specifically designed for this study) and the Voice Handicap Index-10 (VHI-
10) (Jacobson et al, Am J Speech Lang Pathol 6:66–70, 1997) to measure the symptoms of their dysphonia and the
impact of the disease on their quality of life.
Two speech-language pathologists and two laryngologists used the Voice Arrest Measure (VAM) (specifically
designed for this study) and the USDRS to independently rate voice recordings of 56/60 subjects.
Results: The mean VHI-10 score was 21.3 which is clinically significant. The results of the DSQ and the USDRS were
highly correlated. The most severe symptoms identified by both subjects and clinicians were roughness, strain-
strangled voice quality, and increased expiratory effort. Voice arrest, aphonia, and tremor were uncommon. Subjects
rated their current voice quality at the time of reinjection (i.e., at the time of the study) as significantly better than
at the time of their initial AD-FLD diagnosis (p < 0.0001). Inter-clinician reliability on the USDRS was significant at
the 0.001 level.
Conclusions: The findings from the VHI-10 suggest that AD-FLD has a profound impact on quality of life. The
results of the DSQ and the USDRS suggest that there is a strong correlation between subjects’ perception and
clinicians’ assessment of the individual symptoms and the severity of the dysphonia. The findings from the VAM
suggest that voice arrests are infrequent in subjects with AD-FLD who are receiving ongoing BoNT injections. The
strong inter-clinician reliability on the USDRS suggests that it is an appropriate measure for identifying symptoms
and severity of AD-FLD.
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Background
Patients with AD-FLD whose management involves on-
going injections of BoNT schedule reinjection based on
the reemergence of their symptoms. [1] In addition to
the patient’s report of symptoms, clinicians rely on med-
ical history, visualization of the vocal folds, and the vocal
phenomena associated with AD-FLD (e.g., strained-
strangled voice quality, roughness, and increased expira-
tory effort) to determine the severity of the dysphonia
and make treatment decisions. [2–4] The reliability of
perceptual ratings between laryngologists and speech-
language pathologists, however, is not well documented.
Further, the literature related to AD-FLD has not com-
pared clinicians’ ratings and subjects’ perception of these
voice symptoms.
It is well accepted that voice problems may impede
the development of social relationships as well as nega-
tively affect educational, and vocational growth [5–10].
Although the VHI-10 [5] has been used to measure the
impact of AD-FLD on quality of life, it does not chron-
icle the patient’s perception of specific vocal symptoms
or the severity of the dysphonia associated with this
complex, neurological disorder. [5–8] To this end, the
investigators developed The Disease Symptom Question-
naire (DSQ) (see Additional file 1), a self-rating instru-
ment on which subjects identify the specific symptoms
associated with AD-FLD and rate their severity. We can
then examine the relationship between patients’ percep-
tion documented on the DSQ with clinicians’ ratings
from the USDRS [11].
Historically, voice arrest has been described as a cen-
tral phenomenon and a necessary component in the
diagnosis of AD-FLD. [12–15] Nevertheless, in our clin-
ical experience voice arrest has been relatively infre-
quent. The Voice Arrest Measure (VAM) was developed
to document the frequency and duration of voice arrest
during connected speech.
As is the case with many medications, BoNT washes
out of the system over time requiring ongoing re-
injection in order to maintain the patient’s improvement
in voice production. The expected duration of benefit
from injections is three to four months, with subjects re-
quiring ongoing reinjections to maintain an easy, effi-
cient manner of phonation. [16–20] The patient
determines when it is time to seek reinjection, but the
criteria for their decision remain unclear. Thus far, no
studies have compared the subjects’ rating of symptoms
at baseline with those ratings just prior to reinjection to
determine whether BoNT treatment may alter the dis-
ease process.
This study has five aims: first, to ascertain the relation-
ship between the VHI-10 and the DSQ; to compare clini-
cians’ ratings from the USDRS to the subjects’ perceptual
ratings from the DSQ; to identify the subjects’ perception
of changes in their dysphonia since diagnosis as measured
by the DSQ; to determine the frequency of voice arrests
based on the (VAM); and, finally, to measure the inter-
clinician (i.e., two laryngologists and two speech-language
pathologists) reliability from the ratings on the USDRS.
Methods
Subjects
Between March 20 and July 17, 2012, sixty adults (forty-
two females 70% and 18 males 30%) suffering from AD-
FLD presented to a single clinical research center for
continuing treatment with injections of BoNT. Subjects
mean age was 60.78 years (SD 14.13) and the mean time
between diagnosis of AD-FLD and participation in the
study was 16.8 years (SD 9) with a mean age at the onset
of symptoms of 46.05 years (SD 14.28). Data were col-
lected just prior to reinjection when subjects self-
determined that the symptoms had deteriorated to the
point when reinjection was necessary. The mean interval
between the previous injection of BoNT and participa-
tion in the study was 20 weeks (SD 12.04), with 49/52
(94%) having received between five and forty injections.
The inclusion criteria for this study were based on a
previous diagnosis of AD-FLD, participation in ongoing
laryngeal injections of botulinum toxin (BoNT) to
minimize symptoms, and the subjects reported benefit
from BoNT injections. Subjects had self-selected to re-
turn for continuing BoNT management of their voice
symptoms when the benefits of the BoNT injections had
diminished. Exclusion criteria included co-existing upper
respiratory tract infection, concomitant neurological dis-
orders, and non-neurological laryngeal pathologies. Al-
though 100% of the subjects were known to the
laryngologists, only 5% of the subjects were known to
the speech-language pathologists.
The subjects gave informed consent to participate in a
video recording of a voice assessment and to complete
self-evaluation questionnaires (Voice Handicap Index-
104 and Disease Symptom Questionnaire) as part of the
study. This study was approved by the Institutional




The Voice Handicap Index-10 (VHI-10) [5] measures
the impact of the voice disorder on the patients’ quality
of life.
DSQ
The Disease Symptom Questionnaire (DSQ) (see
Additional file 1) was designed as part of this study
to ascertain the subjects’ perception of the individual
characteristics and severity of the voice problem at the
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time of initial diagnosis and at the time of the study. Sub-
jects were asked to document their current age, medical
comorbidities, age at diagnosis, and time since initial diag-
nosis, and since last injection. The authors designed the
DSQ to parallel the symptoms rated on the Unified Spas-
modic Dysphonia Rating Scale (USDRS) ensuring that the
subjects would rate the same symptoms as the otolaryn-
gologists and speech-language pathologists (e.g., severity
of dysphonia, hoarse-rough-husky voice quality, strain-
strangled, increased expiratory effort).
The DSQ rates the severity of the current symptoms
and the symptoms at diagnosis using a 5-point interval
scale (i.e., mild, mild-moderate, moderate, moderate-
severe or severe). One question asks subjects to compare
the severity of their symptoms at diagnosis to their
symptoms at the time of participation in the study using
a 3-point interval scale (i.e., less severe than before treat-




The Unified Spasmodic Dysphonia Rating Scale (USDRS)
[11] provides a framework for clinicians to rate the
individual characteristics and the severity of a subject’s
dysphonia using a 7-point Likert scale.
VAM
The Voice Arrest Measure (VAM) (see Additional file 2)
was designed as part of this study for clinicians to iden-
tify the occurrence and duration of each voice arrest
during the oral reading of the first paragraph of the
Rainbow Passage. [21] This scale is based on the Stuttering
Severity Index (SSI). [22] The duration of each voice arrest
identified on the VAM ranges from momentary (< 1 s),
brief (1–2 s), or long (>2 s in duration).
Procedures
A student intern recorded voice samples in a quiet room
on a Kay/Pentax VLS 1190 STK distal chip camera
system with an Audio-Technica Pro 8HEmW head-
mounted microphone placed 4 in. from the subjects’
mouth. The subjects read the first paragraph of the
Rainbow Passage aloud, described the Cookie Theft pic-
ture [23], and counted from eighty to eighty-nine. Two
laryngologists and two speech-language-pathologists in-
dependently reviewed the video/audio recordings in a
quiet room and rated the severity of the voice symptoms
on the USDRS. The mean of the severity of dysphonia
rated by the four clinicians was calculated and compared
to each subject’s ratings on the DSQ. The clinicians
reviewed the Rainbow Passage a second time and used
the VAM to identify the occurrence and duration of
voice arrest.
Information pertaining to age at data collection and
symptom onset, number of years since initial diagnosis
of AD-FLD, time since first BoNT injection, number of
BoNT injections, and time since most recent BoNT in-
jection was obtained on the DSQ and analyzed with de-
scriptive statistics.
Inter-clinician reliability for the severity of dysphonia
and individual voice symptoms evaluated on the USDRS
was calculated using SPSS version 23 interclass correl-
ation coefficient. Paired sample T-tests were used to
compare the subject’s ratings (DSQ) of the severity of
symptoms with the clinicians’ ratings (USDRS). The re-
lationship between the DSQ and the USDRS was calcu-
lated with a two-tailed correlation. Due to the
comparative infrequency of voice arrest identified by the
clinicians on the VAM, only descriptive statistics were
used to describe these data.
Results
The impact of AD-FLD on quality of life
The mean VHI-10 score was 21.3 (+/−9.6) with 86.7% of
subjects scoring greater than 11, which indicates a voice
handicap that substantially affects quality of life. Subjects
identified symptoms across all three domains included
on the VHI-10 (i.e., functional, physical, and emotional).
The VHI-10 scores were positively correlated with the
overall severity of dysphonia on the DSQ and negatively
correlated with age at the time of diagnosis such that
those subjects who were younger at the time of diagno-
sis reported higher VHI-10 scores. The VHI-10 was not
correlated with number of injections, time since diagno-
sis, or time since previous BoNT injection. See Table 1.
Correlations between the Subject’s ratings of the current
severity of the Dysphonia and the individual voice
symptoms
Pearson analysis revealed a strong positive correlation (see
Table 2) between the subjects’ ratings on the DSQ of
severity of dysphonia and the individual symptoms of
strain-strangled, roughness, voice tremor, and voice arrest.
Relationship between the VHI-10 and the DSQ
Correlations between subjects’ ratings on the VHI-10
and the individual DSQ items were significant for sever-
ity of dysphonia, strain-strangled voice quality, rough-
ness, voice tremor, and voice arrest (see Table 3). These
positive correlations suggest that more severe voice (e.g.,
roughness) and sensory (e.g., increased expiratory effort)
symptoms are associated with greater handicap as
assessed on the VHI-10.
Relationship between USDRS and DSQ
The similarity between the findings on the subjects’
DSQ and the clinicians’ USDRS was highly correlated
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for current severity of dysphonia, strain-strangled voice
quality, roughness, voice arrest, and increased expiratory
effort, but not for voice tremor (see Table 4).
Subject’s perception of changes in voice symptoms since
original diagnosis
All subjects reported that at the time of their original
diagnosis of AD-FLD their voice symptoms were worse
than at the time of this study. This perceived reduction
in symptom severity was statistically significant for all
symptoms except roughness. See Table 5.
Clinician ratings on the USDRS
Due to technical errors on four of the recordings, only
56/60 of the voice recordings were analyzed by four
clinicians. Two speech-language pathologists and two
laryngologists listened independently to the recording of
each subject’s first paragraph of the Rainbow Passage
(fifty-one words), description of the Cooke Theft Picture,
and counting from eighty to eighty-nine. They then
identified and rated the severity of the individual symp-
toms and overall severity of the dysphonia using the
USDRS. The mean score for the severity of dysphonia was
4.2 (moderate impairment). The mean for roughness,
strain-strangled, and increased expiratory effort was 4 in-
dicating that these were the most remarkable symptoms.
Symptoms of voice arrest, aphonia, and breathiness were
mild with a mean of 1.
During a second evaluation of the recordings of the
first paragraph of the Rainbow Passage, voice arrest was
identified and timed by the four clinicians, and only 21/
56 subjects, (38.1%) exhibited this symptom. Of those
twenty-one individuals, 16 (28.6%) exhibited infrequent
voice arrest (i.e., one or two instances of voice arrest),
three (.05%) had occasional voice arrest (i.e., three to 10
occurrences of voice arrest), and just two (.03%) had
more than 10 voice arrests. Eighteen (32%) of these sub-
jects demonstrated momentary voice arrest (< 1 s), three
(.05%) had brief voice arrest (1–2 s), but none had long
voice arrest (> 2 s). Due to the infrequency of voice ar-
rest, only descriptive statistics were performed.
Inter-clinician reliability for rating vocal Symptomatology
on USDRS
Four clinicians independently rated the severity of the
dysphonia and the individual vocal symptoms on the
USDRS for 56/60 subjects. Assessment of inter-clinician
reliability for the clinician ratings was statistically





Overall Severity of Dysphonia on the
DSQ
0.536 .000*
Age at Time of Diagnosis −0.328 .011*
Number of Injections 10.162 .25
Time Since Diagnosis −0.049 .71
Duration Since Previous BoNT Injection −0.09 .94
*Finding was statistically significant at the .01 level
Table 2 Correlations Between the Subjects’ Ratings of the
Current Severity of the Dysphonia and the Individual Voice















Subjects’ Ratings Voice Arrest 0.564 0.000*
*All findings were statistically significant at the 0.01 level
Table 3 Correlations Between Ratings on the VHI-10 and Severity
of Current Symptoms on DSQ N = 56




Subjects’ Ratings of Severity of
Dysphonia
0.474 0.000*
Subjects’ Ratings Strain-Strangled 0.417 0.001*




Subjects’ Ratings Voice Tremor 0.539 0.000*
Subjects’ Ratings Voice Arrest 0.458 0.000*
*Findings was statistically significant at the .01 level
Table 4 Correlation Between Subjects’ and Clinicians’ Ratings of
Voice Symptoms N = 56
Voice Symptom Pearson Correlation Sig (2-tailed)
Dysphonia 0.353 0.008*
Strain-Strangled Voice Quality 0.389 0.003*
Roughness 0.466 0.000*
Voice Arrest 0.502 0.000*
Increased Expiratory Effort 0.454 0.000*
Voice Tremor 0.216 0.109
Note: All clinician ratings were made during review of the video recording of
the Rainbow Passage and description of the Cookie Theft picture
*Findings were statistically significant at the .01 level
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significant, yielding a Cronbach Alpha of .905 for all pa-
rameters (see Table 6). The interclass correlations were
significant for all symptoms on the USDRS except apho-
nia. See Tables 6 and 7. This high inter-clinician reliabil-
ity may be associated with the clinician’s access to visual
as well as audio information, which parallels the clinical
assessment protocol.
Discussion
The VHI-10 is frequently used to measure the impact of
a voice problem on a patient’s quality of life. The present
study asked whether the subjects’ perception of handicap
as identified on the VHI-10 is correlated with the sever-
ity of voice symptoms associated with AD-FLD and se-
lective medical history as identified on the DSQ (i.e.,
time since initial diagnosis, time since last injection, age
at diagnosis, current age, total number of BoNT injec-
tions). The subjects’ perception of handicap as identified
on the VHI-10 was positively correlated with the severity
of the voice symptoms and negatively correlated with
subjects’ age at the time of diagnosis. The strong positive
correlation between the subjects’ ratings on the VHI-10
and the DSQ (e.g., dysphonia, strain-strangled, rough-
ness, increased expiratory effort) suggests that the handi-
cap associated with AD-FLD is related, not only to the
severity of the dysphonia, but to the severity of the indi-
vidual symptoms. Furthermore, subjects who were youn-
ger at the age of diagnosis (16–30 years) indicated
greater handicap on the VHI-10 than those who were
older when the symptoms began. This finding suggests
that the psychosocial aspects of AD-FLD are not only
relevant to the effectiveness of long-term management
but require additional research to better understand
their impact on quality of life.
Prerequisite to the effective management of patients
with AD-FLD is agreement between the laryngologist and
the speech-language pathologist with respect to the mani-
festations of the disease and its severity. Robust inter-
clinician reliability ratings on the USDRS suggests that
these clinicians are rating similar phenomena. Further, the
strong correlation between the clinicians’ ratings on the
USDRS and the subjects’ ratings on the DSQ suggests that
clinicians and patients are identifying similar features and
estimating the severity in an analogous way.
To date there has been little research investigating
subjects’ perception of changes in their symptoms since
the time of diagnosis. To that end, the current study asked
subjects to compare the severity of their dysphonia as well
as the individual characteristics at the time of the original
diagnosis and then at the time of the study. All subjects
rated the severity of their symptoms (with the exception of










Severity of dysphonia Q1, Q2 4.47 (0.68) 3.19 (0.89) <0.00001*
Strain-Strangled Voice Quality (effortful
phonation)
Q8, Q9 4.21 (0.86) 3.02 (1.00) <0.00001*
Voice arrest (voice cuts off) Q3, Q4 4.20 (0.97) 2.89 (1.02) <0.00001*
Roughness (hoarse / husky) Q5, Q7 3.41 (1.40) 3.01 (1.18) 0.10000
Voice tremor (shaking voice) Q10, Q11 3.76 (1.31) 2.71 (1.19) 0.00002*
Increased expiratory effort Q12, Q13 4.21 (0.90) 3.07 (1.11) <0.00001*
Note: The DSQ symptom severity rating scale is a 5-point scale (i.e., 1 = mild, 2 = mild-to-moderate, 3 = moderate, 4 = moderate-to-severe, and
5 = severe). Q = question
*Findings were statistically significant at the .01 level





Reliability across all parameters
on USDRS
0.905 <0.001*
*The reliability of clinician ratings of all perceptual symptoms was significant
Table 7 Inter-Clinician Reliability of Symptoms on the USDRS




Severity of Dysphonia 0.939 <0.001*
Roughness 0.840 <0.001*
Breathiness 0.444 0.003*
Strain-Strangled Quality 0.849 <0.001*
Abrupt Voice Initiation 0.755 <0.001*
Voice Arrest 0.413 0.007*
Aphonia 0.241 0.098




Speech Rate 0.694 <0.001*
Intelligibility 0.688 <0.001*
Note: All clinician ratings were made during review of the video recording of
the Rainbow Passage and description of the Cookie Theft picture
*The reliability of clinician ratings of perceptual symptoms was statistically
significant at the .01 level
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roughness) to be significantly more serious at the time of
initial AD-FLD diagnosis than at the time of the study.
Tremor and voice arrest were the two symptoms that were
identified as having the greatest continuing improvement.
At the time of diagnosis of AD-FLD, the mean severity of
tremor and voice arrest was 4 on the DSQ (i.e., moderate-
to-severe), but at the time of the study the mean rating on
the DSQ was 2 (i.e., mild-to-moderate). This perceived re-
duction in severity raises questions as to whether the occur-
rence of voice arrest is potentially more responsive to
treatment with BoNT than are other symptoms (e.g.,
roughness). Alternatively, do subjects develop adaptive be-
havioral strategies to minimize the frequency of voice arrest
during connected speech, or is it the case that subjects
overestimate the incidence of voice arrest at onset due to
recall bias? If so, why was the severity of voice arrest and
tremor overestimated more frequently than other symp-
toms (e.g., roughness) at the time of diagnosis?
Further research is necessary to explore whether voice
arrest is more responsive to BoNT injections or behav-
ioral control than other symptoms. Moreover, the im-
provement of AD-FLD symptoms since onset may result
from an alteration in sensory feedback. The effect of
BoNT injections on sensory pathways is an area of active
research. It is hypothesized that BoNT alters sensory
feedback in dystonia, resulting in improvement in symp-
toms long after the BoNT has dissipated. Individuals
with oromandibular dystonia (OMD) and blepharo-
spasm, for example, have noted improvement in their
OMD symptoms following injection of BoNT into the
orbicularis oculi alone. [24]
The VAM was used to identify voice arrests in first
paragraph of the Rainbow Passage. Clinicians identified
voice arrest in only 21/56 (38%) subjects. Several pos-
sible explanations may account for the infrequent occur-
rence of voice arrest in this subject population: voice
arrest may not be a predominant characteristic of AD-
FLD; voice arrest may continue to diminish following
BoNT treatment; or subjects may learn to compensate
for voice arrest more easily than for other symptoms.
On the surface, it would be expected that clinicians fa-
miliar with spasmodic dysphonia would be as effective at
documenting the incidence of voice arrest as with the
occurrence of other voice symptoms. Further research is
necessary to explore these alternative hypotheses.
Conclusions
The diagnosis of AD-FLD is based on clinical symptoms
and medical history. The high inter-clinician reliability
of perceptual ratings by laryngologists and speech-
language pathologists based on the USDRS, and the high
correlation of clinician ratings with subjects’ ratings from
the DSQ suggest that clinicians and subjects are rating
similar phenomena using comparable criteria. The ratings
of severity of dysphonia for both clinicians and subjects
are related to the interaction of the symptoms and not to
any single symptom. For subjects and clinicians alike, the
most severe and frequently identified symptoms at the
time of assessment were roughness, strain-strangled voice
quality, and increased expiratory effort. Subjects and clini-
cians judged aphonia and voice tremor to be infrequent
and less severe than other symptoms. The occurrence and
duration of voice arrest as measured by the VAM were in-
frequent and relatively brief.
The severity of the handicap identified on the VHI-10
was strongly correlated, not only with greater severity of
voice symptoms, but with a younger of age of onset of
AD-FLD. These findings suggest that future research
that addresses the psychosocial impact of AD-FLD in
younger individuals may provide information that will
enhance treatment and the quality of life for individuals
suffering from adductor focal laryngeal dystonia.
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